A double-blind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression

J S March; K A Kobak; J W Jefferson; J Mazza; J H Greist

A double-blind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression

J Clin Psychiatry. 1990 May;51(5):200-2.

Authors

J S March¹, K A Kobak, J W Jefferson, J Mazza, J H Greist

Affiliation

¹ Department of Psychiatry, University of Wisconsin Hospital, Madison 53792.

PMID: 2110560

Abstract

The authors employed a double-blind, placebo-controlled design to investigate the effectiveness of fluvoxamine versus imipramine in 54 outpatients with moderate major depression. Fluvoxamine proved superior to placebo but not to imipramine on the Hamilton Rating Scale for Depression and the Montgomery and Asberg Depression Rating Scale. Nausea and hyperarousal were the most common side effects in the fluvoxamine-treated patients.

Publication types

Clinical Trial
Comparative Study
Controlled Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Ambulatory Care*
Antidepressive Agents / therapeutic use*
Clinical Trials as Topic
Depressive Disorder / drug therapy*
Depressive Disorder / psychology
Double-Blind Method
Fluvoxamine
Humans
Imipramine / therapeutic use*
Middle Aged
Oximes / therapeutic use*
Placebos

Substances

Antidepressive Agents
Oximes
Placebos
Fluvoxamine
Imipramine